Decreased catalytic function with altered sumoylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts

Arthritis Research and Therapy

Volumn 13, Issue 4, 2011, Pages

  Zhou, Xiaodong ^a   Lin, Wei ^a   Tan, Filemon K ^a   Assassi, Shervin ^a   Fritzler, Mavin J ^b   Guo, Xinjian ^a   Sharif, Roozbeh ^a   Xia, Tom ^c   Lai, Syeling ^d   Arnett, Frank C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c RICE UNIVERSITY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; SUMO 1 PROTEIN; TOP1 PROTEIN, HUMAN;

ARTICLE; CATALYSIS; CELL STRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SUPERCOILING; FIBROSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN FIBROBLAST; SKIN FIBROSIS; SUMOYLATION; WESTERN BLOTTING; BIOCATALYSIS; CELL NUCLEUS; ENZYMOLOGY; FEMALE; FIBROBLAST; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC SCLEROSIS;

BIOCATALYSIS; BLOTTING, WESTERN; CELL NUCLEUS; DNA TOPOISOMERASES, TYPE I; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SCLERODERMA, SYSTEMIC; SUMOYLATION; TRANSFECTION;

EID: 79961162197     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3435     Document Type: Article

References (28)

1. Tamby MC, Chanseaud Y, Guillevin L, Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003, 2:152-157. 10.1016/S1568-9972(03)00004-1, 12848956.
2. Steen VD. The many faces of scleroderma. Rheum Dis Clin N Am 2008, 34:1-15.
3. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". Arthritis Rheum 1991, 34:1495-1501.
4. Maul GG, French BT, van Venrooij WJ, Jimenez SA. Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cell before anaphase. Proc Natl Acad Sci USA 1986, 83:5145-5149. 10.1073/pnas.83.14.5145, 323907, 3014535.
5. Diot E, Giraudeau B, Diot P, Degenne D, Ritz L, Guilmot JL, Lemarie E. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?. Chest 1999, 116:715-720. 10.1378/chest.116.3.715, 10492277.
6. Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH. Scl 70 antibody--a specific marker of systemic sclerosis. Br J Dermatol 1986, 115:393-401. 10.1111/j.1365-2133.1986.tb06233.x, 3535866.
7. Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000, 43:1074-1084. 10.1002/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E, 10817562.
8. Bunn CC, Black CM. Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol 1999, 117:207-208. 10.1046/j.1365-2249.1999.00990.x, 1905344, 10444248.
9. Leppard JB, Champoux JJ. Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma 2005, 114:75-85. 10.1007/s00412-005-0345-5, 15830206.
10. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002, 3:430-440. 10.1038/nrm831, 12042765.
11. Li M, Guo D, Isales CM, Eizirik DL, Atkinson M, She JX, Wang CY. SUMO wrestling with type 1 diabetes. J Mol Med 2005, 83:504-514. 10.1007/s00109-005-0645-5, 15806321.
12. Meinecke I, Cinski A, Baier A, Peters MA, Dankbar B, Wille A, Drynda A, Mendoza H, Gay RE, Hay RT, Ink B, Gay S, Pap T. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc Natl Acad Sci USA 2007, 104:5073-5078. 10.1073/pnas.0608773104, 1829266, 17360386.
13. Rallabhandi P, Hashimoto K, Mo YY, Beck WT, Moitra PK, D'Arpa P. Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin. J Biol Chem 2002, 277:40020-40026. 10.1074/jbc.M200388200, 12149243.
14. Mo YY, Yu Y, Shen Z, Beck WT. Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. J Biol Chem 2002, 277:2958-2964. 10.1074/jbc.M108263200, 11709553.
15. . Subcommittee for Scleroderma, Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088, Subcommittee for Scleroderma, Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
16. Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, Leroy EC, Fritzler MJ. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996, 39:1151-1160. 10.1002/art.1780390712, 8670324.
17. Buckwalter CA, Lin AH, Tanizawa A, Pommier YG, Cheng YC, Kaufmann SH. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res 1996, 56:1674-1681.
18. Christensen MO, Krokowski RM, Barthelmes HU, Hock R, Boege F, Mielke C. Distinct effects of topoisomerase I and RNA polymerase I inhibitors suggest a dual mechanism of nucleolar/nucleoplasmic partitioning of topoisomerase I. J Biol Chem 2004, 279:21873-21882. 10.1074/jbc.M400498200, 15014084.
19. Mao Y, Mehl IR, Muller MT. Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status. Proc Natl Acad Sci USA 2002, 99:1235-1240. 10.1073/pnas.022631899, 122173, 11805286.
20. Hsu TC, Lee TL, Tsay GJ. Autoantigen components recognizable by scleroderma sera are exported via ectocytosis of fibroblasts. Br J Rheumatol 1997, 36:1038-1044. 10.1093/rheumatology/36.10.1038, 9374918.
21. Henault J, Tremblay M, Clement I, Raymond Y, Senecal JL. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004, 50:3265-3274. 10.1002/art.20515, 15476238.
22. Zhou X, Lee JE, Arnett FC, Xiong M, Park MY, Yoo YK, Shin ES, Reveille JD, Mayes MD, Kim JH, Song R, Choi JY, Park JA, Lee YJ, Lee EY, Song YW, Lee EB. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum 2009, 60:3807-3814. 10.1002/art.24982, 2829245, 19950302.
23. Arnett FC, Gourh P, Shete S, Ahn CW, Honey R, Agarwal SK, Tan FK, McNearney T, Fischbach M, Fritzler MJ, Mayes MD, Reveille JD. Major Histocompatibility Complex (MHC) class II alleles, haplotypes, and epitopes which confer susceptibility or protection in the fibrosing autoimmune disease systemic sclerosis: analyses in 1,300 Caucasian, African-American and Hispanic cases and 1,000 controls. Ann Rheum Dis 2010, 69:822-827. 10.1136/ard.2009.111906, 2916702,2916702, 19596691.
24. Lee MP, Brown SD, Chen A, Hsieh TS. DNA topoisomerase I is essential in Drosophila melanogaster. Proc Natl Acad Sci USA 1993, 90:6656-6660. 10.1073/pnas.90.14.6656, 46991, 8393572.
25. Morham SG, Kluckman KD, Voulomanos N, Smithies O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol Cell Biol 1996, 16:6804-6809. 231683, 8943335.
26. Miao ZH, Player A, Shankavaram U, Wang YH, Zimonjic DB, Lorenzi PL, Liao ZY, Liu H, Shimura T, Zhang HL, Meng LH, Zhang YW, Kawasaki ES, Popescu NC, Aladjem MI, Goldstein DJ, Weinstein JN, Pommier Y. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res 2007, 67:8752-8761. 10.1158/0008-5472.CAN-06-4554, 17875716.
27. Chen M, Dittmann A, Kuhn A, Ruzicka T, von Mikecz A. Recruitment of topoisomerase I (Scl-70) to nucleoplasmic proteasomes in response to xenobiotics suggests a role for altered antigen processing in scleroderma. Arthritis Rheum 2005, 52:877-884. 10.1002/art.20962, 15751092.
28. Ene-Stroescu D, Ellman MH, Peterson CE. Topotecan and the development of scleroderma or a scleroderma-like illness. Arthritis Rheum 2002, 46:844-845. 10.1002/art.10098, 11920426.